Deep-learning algorithm spots carotid calcium on CT exams
A deep-learning algorithm performs comparably to human readers when it come...Read more on AuntMinnie.comRelated Reading: Everyone wins when AI becomes seamless for radiologists RapidAI launches new stroke app Use of CTA, CT perfusion up -- but for the right reasons CT mobile stroke units improve patient outcomes Do angio before CT in acute stroke patients, Barcelona team urges (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 1, 2021 Category: Radiology Source Type: news

Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
U.S. Food and Drug Administration published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy by means of greater safety compared to Xy... Biopharmaceuticals, FDA Jazz Pharmaceuticals, Xywav, Cataplexy, Narcolepsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2021 Category: Pharmaceuticals Source Type: news

A key player in cell death moonlights as a mediator of inflammation
(Kanazawa University) Researchers from Kanazawa University have found that gasdermin D, a protein known to be involved in cell death, is crucial for maturation and release of interleukin-1α, an important inflammatory mediator. When the inflammasome is activated, caspase-1 cleaves gasdermin D into two parts: one of these parts travels to the membrane, where it forms a pore that allows calcium influx and activation of calpains, promoting interleukin-1α activation and exit from cells. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 18, 2021 Category: Biology Source Type: news

FDG-PET shows lipophilic statin users at higher risk of dementia
FDG-PET scans showed patients taking lipophilic statins may have more than doubl...Read more on AuntMinnie.comRelated Reading: PET promises new approaches in detecting atherosclerosis USPSTF advises against carotid artery stenosis screening PET shows cardiac meds may reduce beta-amyloid buildup High calcium density on CCTA linked to lower risk of ACS USPSTF opens review of carotid stenosis screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2021 Category: Radiology Source Type: news

OsteoMD, Developed by 1MD, Receives Taste for Life ’s ‘2021 Women’s...
Scale Media’s nutrition brand, 1MD reformulates OsteoMD bone health supplement to include recommended daily dose of calcium(PRWeb June 15, 2021)Read the full story at https://www.prweb.com/releases/osteomd_developed_by_1md_receives_taste_for_lifes_2021_womens_essentials_award_for_best_bone_support_supplement/prweb17998064.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 15, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and w...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

JAMA Internal Medicine stirs debate on coronary CT
Coronary CT angiography exams and coronary artery calcium scoring scans ar...Read more on AuntMinnie.comRelated Reading: CTA shows the effect of job stress on the heart Machine learning plus CT boosts prediction of major coronary events CCTA shows coronary plaque burden higher in people with HIV CCTA radiomics yields insights into nature of coronary artery disease Better chest CT CAC reporting avoids unnecessary exams (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 7, 2021 Category: Radiology Source Type: news

Space travel weakens our immune systems: Now scientists may know why
(University of California - San Francisco) Microgravity in space perturbs human physiology and is detrimental for astronaut health, a fact first realized during early Apollo missions when astronauts experienced inner ear disturbances, heart arrhythmia, low blood pressure, dehydration, and loss of calcium from their bones after their missions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 7, 2021 Category: International Medicine & Public Health Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors, follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. Today’s BTD marks the 11th received by Janssen’s Oncology The...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlighting ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
May 24, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today follow-up data from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of the investigational product talquetamab, the only off-the-shelf T-cell redirecting bispecific antibody in clinical development to target both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells (NCT03399799).[1],[2],[3] With a median follow-up of more than six months, updated results in 30 patients with relapsed or refractory multiple myeloma treated with talquetamab by subcutaneous (SC) administration at the recommended P...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen ’s Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
We reported initial findings for teclistamab at ASCO 2020, and study updates have observed a deepening of responses that have shown to be durable in a significant percentage of patients with relapsed or refractory multiple myeloma,” said Amrita Y. Krishnan, M.D., Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and Chief, Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, and study investigator. “Teclistamab exposure was sustained across the dosing interval and exceeded target levels, and consistent T-cell activation was observed. ...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

CT Scans for Breast Cancer Radiotherapy Also Show Cardiovascular Risk CT Scans for Breast Cancer Radiotherapy Also Show Cardiovascular Risk
Coronary-artery calcium measured automatically on radiotherapy-planning CT scans in women being treated for breast cancer may be used to spot those at increased risk for CVD, researchers say.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 17, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

' Calcium Imbalance' Linked to Bipolar Severity'Calcium Imbalance' Linked to Bipolar Severity
Calcium homeostasis, rather than just serum vitamin D levels, is linked to adverse outcomes in bipolar disorder, with parathyroid hormone a promising marker of severity, new research suggests.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 11, 2021 Category: Internal Medicine Tags: Psychiatry News Source Type: news